Symbiomix
Developing innovative treatments for women’s health conditions.
F-Prime Team
Sector
Life SciencesCategory
TherapeuticsLocation
Newark, NJInitial Investment
2013
Developing innovative treatments for women’s health conditions.
Symbiomix developed the first oral, single dose treatment in the United States for bacterial vaginosis (BV), a common gynecological infection that increases the risk of serious health problems. Symbiomix was acquired by Lupin Pharmaceuticals.